https://www.selleckchem.com/pr....oducts/debio-0123.ht
0 vs. 6.0 months and 21.0 vs. 15.0 months, respectively, p less then 0.001), but the PFS and OS were best in patients with NOM-CRC (9.0 and 35.0 months). Improved OS was associated with R0 resection (23.0 vs. 17.0 months, p less then 0.001). Multivariate analysis indicated that patients with well-differentiated pathology and unilateral ovarian metastasis had a better prognosis. Conclusion Multidisciplinary treatment strategy, including systemic chemotherapy, targeted therapy, and complete surgery, may contribute to the prolongati
Like
Comment
Share
